CAMIVEL CARVAJAL: Open Payments
NPI 1437919917 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,004 in 108 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $458 · 2025 $2,004
Food & beverage: $2,004
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 4 | $335 |
| Otsuka America Pharmaceutical, Inc. | 23 | $275 |
| Novartis Pharmaceuticals Corporation | 19 | $216 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $185 |
| Bayer Healthcare Pharmaceuticals Inc. | 15 | $184 |
| AstraZeneca Pharmaceuticals LP | 2 | $157 |
| Vifor Pharma, Inc. | 9 | $150 |
| AKEBIA THERAPEUTICS INC | 5 | $105 |
| Amgen Inc. | 4 | $85 |
| GlaxoSmithKline, LLC. | 3 | $65 |
Products named: JYNARQUE, Filspari, Fabhalta, JARDIANCE, Kerendia, FARXIGA, Veltassa, Vafseo.
Industry payments across NV — which companies pay providers there.
